BUSINESS

Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted

By Ken Yoshino April 3, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Takeda Pharmaceutical said its ongoing US organizational restructuring — affecting an estimated 634 roles — “does not simply represent a workforce reduction,” emphasizing internal redeployment and continued hiring as part of a broader transformation. The Japanese drug giant told Jiho…

To read the full story

Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026

BUSINESS

Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
Gilead Names Andrew Hexter as Japan President
April 2, 2026
Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
Kei Kaneda Becomes President of Moderna Japan
April 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing

By Sakura Kono

Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…

COLUMN

Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…